Our findings suggest FOXD2-AS1 functions as an oncogene and promotes the tumor progression and metastasis in PTC, which might serve as a promising prognostic biomarker and potential therapeutic target for PTC patients.
The pooled ORs indicated that FOXD2-AS1 upregulation was related to large tumor size (OR = 1.53, 95%CI: 1.26-1.85, p < 0.001), deep invasion depth (OR = 1.99, 95%CI: 1.53-2.58, p < 0.001), distant metastasis (OR = 2.03, 95%CI: 1.69-2.43, p < 0.001) and advanced TNM stage (OR = 1.35, 95%CI: 1.06-1.72, p = 0.0150), but not to lymph node metastasis nor differentiation.
Furthermore, high expression of FOXD2-AS1 was obviously correlated with deep Breslow thickness, present ulceration, high Clark level and distant metastasis in cutaneous melanoma patients.
FOXD2‑AS1 overexpression enhanced the viability and metastasis of HCC cells in vitro and in vivo, as revealed by MTT, wound healing and cell migration assays.